|
Zhongyan Shan (AOTA）
Department of Endocrinology and Metabolism, the First Affiliated Hospital of China Medical University
China
|
Time: 08:00-08:40 (UTC/GMT+8), Dec. 17, 2020
Topic: Iodine and Thyroid Diseases: Lessons from a 20-Year Follow-up
|
|
Biography
Dr. SHAN is the director of the Department of Endocrinology and Metabolism, the First Affiliated Hospital of China Medical University, the Director of National key laboratory of thyroid disease diagnosis and treatment, the vice president of the Chinese Society of Endocrinology (CSE), as well as the Chairman of Chinese Thyroid Association (CTA). She is also a member of AOTA and ATA.
She graduated from China Medical University and received her bachelor's degree and her doctor's degree in 1987 and in 1992, respectively. From 2000 to 2003, she did postdoctoral research in the Department of Pathology, Stanford University School of Medicine. She has been interested in epidemiological, clinical and basic research in thyroid disease more than 20 years since 1998 and has published more than 200 academic articles. Her research achievements focus on iodine and thyroid disease as well as thyroid disorders during pregnancy.
|
Fabian Pitoia (LATS)
Hospital de Clinicas- University of Buenos Aires
Argentina
|
Time: 10:30-11:10 (UTC/GMT+8), Dec. 17, 2020
Topic: Selective Use of Tyrosine Multi-Kinase Inhibitor Therapy in Patients with RR-DTC
|
|
Biography
Fabián Pitoia, MD, PhD. is the chief of the Thyroid Section of the Division of Endocrinology - Hospital de Clínicas “José de San Martín” from the University of Buenos Aires. He is the current President-Elect of the Latin American Thyroid Society. He is a professor of Internal Medicine and Assistant Director of the Career of medical specialists in Endocrinology at the University of Buenos Aires.
Dr Pitoia is mainly dedicated to clinical investigation of thyroid cancer. He is also associate editor of Endocrine and an editorial board member of Endocrine Related Cancer and the Journal of the Endocrine Society.
He has more than 300 pair-reviewed publications and had given more than 300 lectures around the world.
|
Anthony Hollenberg (ATA)
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
The United States of America
|
Time: 14:00-14:40 (UTC/GMT+8), Dec. 17, 2020
Topic: Nuclear Receptor Coregulators: Modulators of Thyroid Hormone Action in Health and Disease
|
|
Biography
Dr. Anthony Hollenberg is the Sanford I. Weill Chair of Medicine in the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and the Physician-in-Chief at NewYork-Presbyterian Hospital. Dr. Hollenberg received his M.D. from the University of Calgary in Canada in 1986. He completed his Internal Medicine residency in 1989 and was Chief Resident in Medicine from 1990 to 1991 at the Beth Israel Hospital. Dr. Hollenberg then completed a fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital in 1993 and was recruited back to Beth Israel to start his laboratory. From 2011 until his recruitment to Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Hollenberg was Chief of the Division of Endocrinology, Diabetes and Metabolism, at Beth Israel Deaconess Medical Center and Director of Clinical and Translational Research Training Programs at Harvard Catalyst and Harvard Medical School where he was also a Professor of Medicine.
|
Rossella Elisei (ETA)
University of Pisa
Italy
|
Time: 08:00-08:40 (UTC/GMT+8), Dec. 18, 2020
Topic: Update in the Treatment of Medullary Thyroid Cancer
|
|
Biography
Rossella Elisei is an Associate Professor of Endocrinology at the University of Pisa. She is an expert clinician mainly involved in the management of thyroid cancer patients. Dr. Elisei received numerous international awards: the Light of Life Foundation for the best thyroid cancer researcher of 2011, the 2018 European Thyroid Association award as distinguished scientist in Thyroid research field, the JCEM award for the best clinical paper 2006, 2012, 2015 and 2016. Dr. Elisei is the author of 220 papers published in peer-reviewed Journals, 55 manuscripts in proceedings of meetings and book chapters, as well as more than 300 abstracts for national and international meetings. She also serves as a reviewer for several peer-reviewed journals and holds memberships in several professional associations. She is PI of several clinical trials for new target therapy in advanced thyroid cancer.
|
Yaron Tomer (ATA)
Department of Medicine at Albert Einstein College of Medicine and Montefiore Health System,The United States of America
|
Time: 10:30-11:10 (UTC/GMT+8), Dec. 18, 2020
Topic: Dissecting the Genetic Architecture of Thyroid Autoimmunity: Implications for Targeted Immune Therapies
|
|
Biography
Dr. Tomer is the Anita and Jack Saltz Chair in Diabetes Research, Professor and Chair of the Department of Medicine at Albert Einstein College of Medicine and Montefiore Health System. Dr. Tomer received his MD degree from the Sackler School of Medicine of Tel Aviv University, and trained in Internal Medicine at Sheba Medical Center, Israel, and in Endocrinology at the Icahn School of Medicine at Mount Sinai in New York. Dr. Tomer’s research program focuses on the immunogenetic, epigenetic, and environmental mechanisms underlying thyroid autoimmunity, and type 1 diabetes, and on targeting these mechanisms in order to develop novel therapies. Among his accomplishments are: discovery that CD40 is a major susceptibility gene for autoimmune thyroid disease (AITD) and dissection of the mechanisms by which it triggers AITD (a discovery that is the basis of a new therapeutic antibody that was recently developed by pharma targeting CD40); identification of an HLA-DR amino acid signature that is associated with both autoimmune diabetes and thyroiditis; identification of new epigenetic mechanisms that trigger autoimmune thyroiditis; and recently discovery of a compound that can block antigen presentation and prevent autoimmune thyroiditis in mouse models. Dr. Tomer published over 180 manuscripts and book chapters and he is frequently invited nationally and internationally to give lectures about his research. Dr. Tomer is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians. He is the recipient of several awards including the American Thyroid Association Van Meter Award recognizing his research accomplishments.
|
Denise Pires de Carvalho (LATS)
Federal University of Rio de Janeiro
Brazil
|
Time: 14:00-14:40 (UTC/GMT+8), Dec. 18, 2020
Topic: Thyroid Disruption: Past, Present and Future
|
|
Biography
Denise P. Carvalho is a Full Professor in Endocrine Physiology and the Rector of the Federal University of Rio de Janeiro. She has been elected the President of the Latin American Thyroid Society (2015-2017), the past President of the Brazilian Thyroid Department of the Brazilian Endocrine Society (2004-2006), and the past Director of Carlos Chagas Filho Institute of Biophysics (2010-2013). She was a member of the editorial board of Endocrinology (2003-2009), senior editor of Endocrine Connections (2015-2019) and a PlosOne Academic Editor. Nowadays, she acts as a reviewer of more than 20 international journals, and evaluated international research grants submitted to the ta Op Tegen Kanker 2014 Dream Team Translational Cancer Research Grant, from the American Association for Cancer Research and for the Fonds de la Recherche Scientifique (FNRS).
Dr. Carvalho has published more than 150 articles in the thyroid field and endocrine disruptors, mainly focused on the mechanisms of iodination reaction and thyroid hormone biosynthesis. She has studied the relation between thyroglobulin iodination and its hormonal contents, thyroperoxidase activity in thyroid lesions and has participated on the biochemical characterization of hydrogen peroxide generation by DuOx in the human thyroid gland. Her group has published outstanding papers on DuOx regulation by iodide and its role in thyroid hormone biosynthesis. She has been the mentor of 31 PhD and 29 MSc students and has written 6 book chapters.
|
Gregory W. Randolph (ATA)
Harvard Medical School; Massachusetts Eye & Ear Infirmary
The United States of America
|
Time: 08:00-08:40 (UTC/GMT+8), Dec. 19, 2020
Topic: Personalization of DTC Initial Management: From Active Surveillance to Extensive Surgery - Why?
|
|
Biography
Gregory W. Randolph MD FACS FACE FEBS (Endocrine) is a Professor of Otolaryngology Head and Neck Surgery and the Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology at Harvard Medical School in the Department of Otolaryngology Head and Neck Surgery and Surgeon at Massachusetts Eye & Ear Infirmary. He trained at Cornell and Harvard Medical Schools. He founded and directs the Division of Thyroid and Parathyroid Endocrine Surgery. Dr. Randolph has a thyroid and parathyroid surgical practice focused on thyroid cancer, benign thyroid surgery and hyperparathyroidism exclusively and sees patients and operating at both Mass Eye and Ear Infirmary and Mass General Hospital.
Dr. Randolph has focused the bulk of his
research on recurrent laryngeal nerve anatomy, preservation and monitoring
during thyroid cancer surgery with focus on importance of laryngeal exam,
recognition of lymph node metastasis and revision cancer surgery. He has lead
thyroid surgical missions to thyroid surgical units in St. Petersburg, Russia,
Guangzhou, China, Kenya, rural India and in the Chernobyl region of the
Ukraine. He founded and directs the
Harvard Thyroid and Parathyroid Surgery Course for surgeons and has directed
international surgical courses in Italy, Germany, Switzerland and Russia. He has
received board certification from the European Union’s Board of Surgery in Neck
Endocrine Surgery. He has published an endocrine surgical text: “Surgery of the Thyroid and Parathyroid Glands” published by Elsevier Saunders now in its second edition as well as a text
centered on surgery of the recurrent laryngeal nerve “The Recurrent and Superior
Laryngeal Nerves” published by Springer Publishers. He served as President and Director of
International Affairs for the American Academy of Otolaryngology Head and Neck
Surgery. He has served as Treasurer and on the executive board of the American
Thyroid Association. He currently serves as chair of the Endocrine Surgery Section
of the American Head and Neck Society and the Board of Directors, Surgical
Liaison for the American Association of Clinical Endocrinology.
|
Ki-Wook Chung (AOTA)
Division of Endocrine Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
|
Time: 10:30-11:10 (UTC/GMT+8), Dec. 19, 2020
Topic: Personalization of DTC Initial Management: From Active Surveillance to Extensive Surgery -When?
|
|
Biography
Dr. Chung graduated from Seoul National University College of Medicine in 1993, and took Ph.D. degree from the same University in 2003. Now He is professor of Department of Surgery, University of Ulsan College of Medicine and also division chief of Division of Endocrine Surgery, Department of Surgery, Asan Medical Center. He also has played a role in many academic societies such as Korean Association of Endocrine Surgeons, Korean Thyroid Association, and International Society of Oncoplastic Endocrine Surgeons.
His main research interests are molecular and clinical prognostic marker of thyroid cancers. Now he is willing to set up novel treatment strategy for secondary hyperparathyrodism. He has published 5 book chapters (two in English, three in Korean) and original research papers more than 80.
|
Graham Williams (ETA)
Imperial College London
The United Kingdom
|
Time: 14:00-14:40 (UTC/GMT+8), Dec. 19, 2020
Topic: Mammalian Development: A New and Critical Role for Thyroid Hormone Receptors
|
|
Biography
Graham Williams is Professor of Endocrinology in the Department of Metabolism, Digestion and Reproduction, Imperial College London. He graduated in medicine from St. Thomas’s Hospital in London, trained in clinical endocrinology at the Queen Elizabeth Hospital in Birmingham, UK and undertook research training at Harvard Medical School in Boston, USA. His research focuses on the genetic origins of bone and cartilage disease and molecular mechanisms of thyroid hormone action in the skeleton. He has received many research prizes including from the UK Society for Endocrinology, the European, Danish, American and British Thyroid Associations, and the European Calcified Tissue Society. Professor Williams served as Treasurer (2010-2016) and President (2016-2019) of the UK Society for Endocrinology and President (2011-2014) of the British Thyroid Association. He is currently President-Elect of the European Thyroid Association (2020-2021) and will serve as President of the ETA from 2021-2023. Professor Williams was elected as a Fellow of the Academy of Medical Sciences in 2019.
|
Jiajun Zhao (AOTA)
Department of Endocrinology and Metabolism, Provincial Hospital affiliated to Shandong First Medical University; Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, China
|
Time: 08:00-08:40 (UTC/GMT+8), Dec. 20, 2020
Topic: The Role of TSH Beyond Thyroid
|
|
Biography
Jiajun Zhao, the Vice president of Shandong First Medical University and the President of Provincial Hospital affiliated to Shandong First Medical University, the head of Institute of Endocrinology and Metabolism in Shandong Academy of Clinical Medicine, the director and professor of Department of Endocrinology and Metabolism,. He received his M.D. and Ph.D. from Shanghai Second Medical University. Dr. Zhao has been focusing on the study of endocrine and metabolic diseases, such as thyroid related disease, type 2 diabetes and insulin resistance syndrome, hereditary endocrine and metabolic diseases caused by single or multiple gene mutation, as well as the research on pathogenesis of endocrine related cancers. Dr. Zhao has received more than 10 grants and published more than 150 scientific papers in peer-reviewed journals. He is on the editorial boards of several journals and the chairman of the Chinese Endocrine Society, member of standing committee in the Chinese Integrated Traditional and Western Medicine Association.
|
Ralf Paschke (ATA)
Departments of Medicine, Oncology, Pathology, and Biochemistry and Molecular Biology & Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Canada
|
Time: 10:30-11:10 (UTC/GMT+8), Dec. 20, 2020
Topic: Molecular Markers as Prognostic Tools to Define Initial Treatment: The Time has Come?
|
|
Biography
Ralf Paschke served as Division Head of Endocrinology at the University of Calgary, Zone Head of Endocrinology in Calgary from July 2015 to May 2019. In November 2015, he was elected as the chair of the provincial endocrine tumour team in Alberta.
Ralf Paschke spent 4 years as a Heisenberg Professor in a molecular laboratory in the Institute of Interdisciplinary Research at the Universite Libre in Brussels, Belgium working on the molecular etiology of hot thyroid nodules and the mechanism of activation of the TSHR. He was appointed Professor of Internal Medicine and Endocrinology at the University of Leipzig in 1995. His major research interests include thyroid cancer, thyroid nodules, thyroid nodule molecular fine needle cytology (FNAC) diagnostics, the TSH-receptor and diseases caused by TSH-receptor mutations. He trained in Pathology, Internal Medicine and Endocrinology in the university hospitals of Frankfurt, Mannheim and Muenster. He served for 9 years as Director of the Medical Department III at Leipzig University with the sections Endocrinology, Diabetes and Nephrology. He was also the coordinator for endocrine research and deputy chairman of the Interdisciplinary Centre for Clinical Research at the University of Leipzig, Germany. He is the author of more than 350 original journal articles, co-author of several thyroid guidelines and serves on the editorial boards of several journals including Thyroid, European Thyroid Journal and repeatedly the JCEM.
|
Mikio Watanabe (AOTA)
Department of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine
Japan
|
Time: 14:00-14:40 (UTC/GMT+8), Dec. 20, 2020
Topic: Genetics of Thyroid Autoimmunity
|
|
Biography
Mikio WATANABE was received the Ph.D. degree in Medical Sciences from Osaka University, Japan. He is Certified thyroid specialist and a councilor of Japanese Thyroid Association. He is now professor of Osaka University Graduate School of Medicine. His research interest includes genetic and epigenetic effects, in thyroid autoimmunity and other medical traits such as laboratory tests. He is also professor in the Center for Twin research, Osaka University, and trying to analyze epigenetic effects in human traits by novel approaches using monozygotic and dizygotic twins.
